Stay updated on IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib
Sign up to get notified when there's something new on the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page.

Latest updates to the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page
- CheckyesterdayChange DetectedBoth screenshots show the same study details with no changes to core information such as title, conditions, interventions, eligibility criteria, enrollment numbers, or primary outcomes; only minor formatting adjustments are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2% 
- Check8 days agoNo Change Detected
- Check29 days agoChange DetectedMajor updates: added government operating status notice and new research citation; updated version to v3.2.0, replacing the previous v3.0.2.SummaryDifference2% 
- Check30 days agoChange DetectedPage version updated to v3.1.0 and a new 2025 citation added; previous version v3.0.2 removed.SummaryDifference0.6% 
- Check45 days agoChange DetectedThe page now shows Revision: v3.0.2 replacing v3.0.1, indicating a new release. The 'Back to Top' element has been removed, suggesting a minor UI cleanup.SummaryDifference0.1% 
- Check52 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.1% 
- Check59 days agoChange DetectedThe webpage has undergone significant updates, including the addition of various facility names and locations across multiple countries, while also removing several previous location entries and terms. Notably, the revision number has been updated from v2.16.12 to v3.0.0.SummaryDifference8% 
Stay in the know with updates to IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib
Enter your email address, and we'll notify you when there's something new on the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page.